Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Jun 07, 2021 8:34am
64 Views
Post# 33338972

RE:RE:PreMarket $5.62 thus far

RE:RE:PreMarket $5.62 thus far

I have one theory but it is as evil as the recapitalization where Thomvest got their 71% share when other funding sources were available in late 2018/ early 2019. Tanking things on purpose and Thomvest/ SALP own this puppy? I can't think of any other reason to put that information out there. There is just no logical reason unless there is a surprise new direction announced this week but, on the same basis that material news should be reported immediately, why would they stagger the news of dropping IPF and not announcing that, for instance, kidney or liver results were surprisingly good. To follow tanking theory, Thomvest could go private and talk to Boehringher and one other for competitive tension and sell off PBI4050 based on 8 clinical studies in data room in summer of 2018 as Thomvest don't want to be in this anymore.

Steve33 wrote:
I totally agree. They are doing an incredible job at keeping the share price down. For what purpose. They own most of the shares so they should want it to shoot up. Any guesses as to why?

 

<< Previous
Bullboard Posts
Next >>